| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6249979 | Transplantation Proceedings | 2013 | 4 Pages |
Abstract
These results indicate that the risk of PCP in OLT recipients is closely related to strong immunosuppressive treatment for acute cellular rejection episodes, suggesting the importance of PCP prophylaxis in these patients. Because most patients developed PCP at around 1 year, it may be advisable to prolong routine post-OLT PCP prophylaxis for 12 months, especially among patients receiving antirejection treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Y.-I. Choi, S. Hwang, G.-C. Park, J.-M. Namgoong, D.-H. Jung, G.-W. Song, T.-Y. Ha, D.-B. Moon, K.-H. Kim, C.-S. Ahn, S.-G. Lee,